Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer,
with treatment options often constrained due to inherent resistance of malignant cells to …

Molecular targeted therapy has revolutionized the landscape of cancer treatment due to
better therapeutic responses and less systemic toxicity. However, therapeutic resistance is a …

According to the invasive nature of glioblastoma, which is the most common form of
malignant brain tumor, the standard care by surgery, chemo-and radiotherapy is particularly …

Cells subjected to treatment with anti-cancer therapies can evade apoptosis through cellular
senescence. Persistent senescent tumor cells remain metabolically active, possess a …

Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Execution of the intrinsic apoptotic pathway is controlled by the BCL-2 proteins at the level of
the mitochondrial outer membrane (MOM). This family of proteins consists of prosurvival (eg …

ABSTRACT Introduction: Myeloid cell leukemia-1 (MCL-1) is an anti-apoptotic member of
the B-cell lymphoma-2 (BCL-2) family of proteins that regulates apoptosis. Elevated levels of …

Myeloid cell leukemia‐1 (MCL1), an antiapoptotic member of the BCL2 family characterized
by a short half‐life, functions as a rapid sensor that regulates cell death and other relevant …

MCL-1 is a well-characterized inhibitor of cell death that has also been shown to be a
regulator of mitochondrial dynamics in human pluripotent stem cells. We used …

The PI3K pathway is commonly activated in breast cancer, with PI3K-AKT pathway inhibitors
used clinically. However, mechanisms that limit or enhance the therapeutic effects of PI3K …